STEFAN R. SCHMIDT, PhD, is Vice President for Downstream Processing at Rentschler Biotechnology. Previously, he served as CSO at ERA Biotech and Associate Director for Protein Science at AstraZeneca. Dr. Schmidt has chaired many international conferences and written several original articles, reviews, and book chapters.
Preface
Contributors
Part I INTRODUCTION
1. Fusion Proteins: Applications and Challenges
Stefan R. Schmidt
2. Analysing and Forecasting the Fusion Protein Market and Pipeline
Mark Belsey and Giles Somer
3. Structural Aspects of Fusion Proteins Determining the Level of Commercial Success
Mark Belsey and Giles Somer
4. Fusion Protein Linkers: Effects on Production, Bioactivity, and Pharmacokinetics
Xiaoying Chen, Jennica Zaro, and Wei-Chiang Shen
5. Immunogenicity of Therapeutic Fusion Proteins: Contributory Factors and Clinical Experience
Vibha Jawa, Leslie Cousens, Anne S. De Groot
Part II THE TRIPLE T PARADIGM: TIME, TOXIN, TARGETING
II a) TIME: FUSION PROTEIN STRATEGIES FOR HALF LIFE EXTENSION
6. Fusion Proteins for Half Life Extension
Stefan R. Schmidt
7. Monomeric Fc Fusion Proteins
Baisong Mei, Susan C. Low, Snejana Krassova, Robert T. Peters, Glenn F. Pierce and Jennifer A. Dumont
8. Peptide-Fc Fusion Therapeutics: Applications and Challenges
Chichi Huang and Ronald V. Swanson
9. Receptor-Fc and Ligand Traps as High Affinity Biological Blockers: Development and Clinical Applications
Aris N. Economides and Neil Stahl
10. Recombinant Albumin Fusion Proteins
Thomas Weimer, Hubert J. Metzner and Stefan Schulte
11. Albumin Binding Fusion Proteins in the Development of Novel Long-Acting Therapeutics
Adam Walker, Gráinne Dunlevy and Peter Topley
12. Transferrin Fusion Protein Therapies: Acetylcholine Receptor-Transferrin Fusion Protein as a Model
Dennis Keefe, Michael Heartlein and Serene Josiah
13. Half Life Extension Through O-Glycosylation Fuad Fares
14. ELP Fusion Technology for Biopharmaceuticals
Doreen M. Floss, Udo Conrad, Stefan Rose-John and Jürgen Scheller
15. Ligand-Receptor Fusion Dimers
Sarbendra L. Pradhananga, Ian R. Wilkinson, Eric Ferrandis, Peter J. Artymiuk, Jon R. Sayers and Richard J. Ross
16. Development of Latent Cytokine Fusion Proteins
Lisa Mullen, Gill Adams, Rewas Fatah, David Gould, Anne Rigby, Michelle Sclanders, Apostolos Koutsokeras, Gayatri Mittal, Sandrine Vessillier and Yuti Chernajovsky
II b) TOXIN: CYTOTOXIC FUSION PROTEINS
17. Fusion Proteins with Toxic Activity
Stefan R. Schmidt
18. Classic Immunotoxins with Plant or Microbial Toxins
Jung Hee Woo and Arthur Frankel
19. Targeted and Untargeted Fusion Proteins: Current Approaches to Cancer Immunotherapy
Leslie A. Khawli, Peisheng Hu, and Alan L. Epstein
20. Development of Experimental Targeted Toxin Therapies for Malignant Glioma
Nikolai G. Rainov and Volkmar Heidecke
21. Immunokinases
Stefan Barth, Stefan Gattenlöhner and Mehmet Kemal Tur
22. ImmunoRNase Fusions
Wojciech Ardelt
23. Antibody Directed Enzyme Prodrug Therapy (ADEPT)
Surinder K. Sharma
24. Tumor Targeted Superantigens
Gunnar Hedlund, Göran Forsberg, Thore Nederman, Anette Sundstedt, Leif Dahlberg, Mikael Tiensuu and Mats Nilsson
II c) TARGETING: FUSION PROTEINS ADDRESSING SPECIFIC CELLS, ORGANS AND TISSUES
25. Fusion Proteins with a Targeting Function
Stefan R. Schmidt
26. Cell-Penetrating Peptide Fusion Proteins
Andrés Muñoz-Alarcón, Henrik Helmfors, Kristin Karlsson and Ülo Langel
27. Cell-Specific Targeting of Fusion Proteins through Heparin-Binding
Jiajing Wang, Zhenzhong Ma, Jeffrey A. Loeb
28. Bone-Targeted Alkaline Phosphatase
José Luis Millán
29. Targeting Interferon Alpha to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery
Jessica Fioravanti, Jesús Prieto, Pedro Berraondo
PART III: BEYOND THE TRIPLE T-PARADIGM
III a) NOVEL CONCEPTS, NOVEL SCAFFOLDS
30. Signal Converter Proteins
Mark L. Tykocinski
31. Soluble T-cell Antigen Receptors
Peter R. Rhode
32. High Affinity monoclonal T-cell receptor (mTCR) fusions
Nikolai M. Lissin, Namir J. Hassan and Bent K. Jakobsen
33. Amediplase
Stefano Evangelista and Stefano Manzini
34. Breaking New Therapeutic Grounds: Fusion Proteins of DARPins and Other Non-Antibody Binding Proteins
H. Kaspar Binz
III b) MULTIFUNCTIONAL ANTIBODIES
35. Resurgence of Bispecific Antibodies
Patrick A. Baeuerle and Tobias Raum
36. Novel Applications of Bispecific DART Proteins
Syd Johnson, Bhaswati Barat, Paul Moore and Ezio Bonvini
37. Strand Exchange Engineered Domain (SEED): A Novel Platform Designed to Generate Mono and Multispecific Protein Therapeutics
Alec W. Gross, Jessica P. Dawson, Marco Muda, Christie Kelton, Sean D. McKenna, and Björn Hock
38. CovX-Bodies
Abhijit Bhat, Olivier Laurent, Rodney Lappe
39. Modular Antibody Engineering: Antigen Binding Immunoglobulin Fc CH3 Domains as Building Blocks for Bi-Specific Antibodies (mAb2)
Maximilian Woisetschläger, Florian Rüker, Geert C Mudde, Gordana Wozniak-Knopp, Anton Bauer and Gottfried Himmler
40. Designer Fusion Modules for Building Multifunctional, Multivalent Antibodies and Immunoconjugates: The Dock-and-Lock Method
Edmund A. Rossi David M. Goldenberg and Chien-Hsing Chang
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.